Coherus Oncology (CHRS) Minority Interest (2014 - 2018)

Coherus Oncology has disclosed Minority Interest across 5 years of filings, most recently posting -$1.3 million for Q2 2018.

• In Q2 2018, Minority Interest fell 4.52% year-over-year to -$1.3 million; the TTM figure through Jun 2018 stood at -$1.3 million (down 4.52% YoY), while the FY2017 annual figure was -$1.3 million, down 9.89% from the prior year.
• Minority Interest came in at -$1.3 million for Q2 2018 at Coherus Oncology, down from -$1.3 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of -$44000.0 in Q4 2014 to a low of -$1.3 million in Q2 2018.
• Average Minority Interest over 5 years is -$872250.0, with a median of -$1.1 million recorded in 2016.
• Year-over-year, Minority Interest slumped 1540.91% in 2015 and slipped 4.52% in 2018.
• Over 5 years, Minority Interest stood at -$44000.0 in 2014, then slumped by 1540.91% to -$722000.0 in 2015, then sank by 62.47% to -$1.2 million in 2016, then fell by 9.89% to -$1.3 million in 2017, then retreated by 4.03% to -$1.3 million in 2018.
• Per Business Quant data, the three most recent Minority Interest figures were -$1.3 million in Q2 2018, -$1.3 million in Q1 2018, and -$1.3 million in Q4 2017.